News & Perspective

Mar 14, 2019

Mar 14, 2019
Mycobacterium tuberculosis bacteria

Trial data support shorter drug-resistant TB regimen

Short-course therapy led to a favorable outcome in 79% of patients, compared with 80% in long-course patients.

Pages

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»